Press release
Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2034
Malignant Pleural Mesothelioma
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70867
Over the next decade, the market will benefit from heightened awareness, stricter occupational safety regulations, and advances in multimodal treatment approaches that aim to improve survival rates.
Market Overview
• Market Size (2024): USD 1.21 billion
• Forecasted Market Size (2034): USD 2.11 billion
• CAGR (2024-2034): ~5.8%
• Key Drivers: Rising adoption of immunotherapy, earlier detection through screening programs, and stricter asbestos control policies.
• Challenges: Aggressive disease progression, treatment resistance, and high therapy costs.
• Leading Players: Bristol Myers Squibb, Merck & Co., Novocure Ltd., Roche Holding AG, Eli Lilly & Company, AstraZeneca plc, and Pfizer Inc.
Segmentation Analysis
By Treatment Type
• Surgery (Extrapleural Pneumonectomy, Pleurectomy/Decortication)
• Chemotherapy (Pemetrexed + Cisplatin/Carboplatin)
• Radiation Therapy
• Immunotherapy (Checkpoint Inhibitors - PD-1/PD-L1, CTLA-4)
• Tumor Treating Fields (TTF)
• Multimodal Therapy
By Histology
• Epithelioid
• Sarcomatoid
• Biphasic
By End Use
• Hospitals & Cancer Centers
• Specialty Clinics
• Academic & Research Institutes
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Segmentation Summary
While chemotherapy remains the standard first-line treatment, checkpoint inhibitors such as nivolumab and ipilimumab are now integrated into guidelines for advanced MPM, with TTF devices showing promise as adjunctive therapy.
Explore Full Report here: https://exactitudeconsultancy.com/reports/70867/malignant-pleural-mesothelioma-market
Regional Analysis
North America
• Holds ~39% of global market share in 2024.
• Strong clinical trial activity for immunotherapy combinations.
• Strict asbestos regulation and established treatment centers.
Europe
• High prevalence in countries with historical asbestos use (UK, Italy).
• EMA approvals expanding immunotherapy adoption.
Asia-Pacific
• Fastest-growing region (CAGR > 7%).
• Rising diagnosis rates in Australia, Japan, and parts of Southeast Asia.
• Gradual introduction of advanced imaging and targeted therapies.
Middle East & Africa
• Increasing awareness programs in GCC countries.
• Limited access to specialized MPM care in rural areas.
Latin America
• Brazil and Chile leading awareness campaigns and improving diagnostic infrastructure.
Regional Summary
While North America and Europe dominate current revenues, Asia-Pacific is expected to see the fastest growth due to improving healthcare access and government-led asbestos safety initiatives.
Market Dynamics
Key Growth Drivers
1. Immunotherapy integration into first-line and maintenance treatment.
2. Global asbestos ban policies reducing future incidence rates while increasing early diagnosis.
3. Development of novel biomarkers for earlier detection.
4. Rising number of multimodal therapy trials.
Key Challenges
1. Limited curative options for advanced MPM.
2. High therapy costs impacting patient access.
3. Therapy resistance in long-term management.
4. Diagnostic delays due to non-specific early symptoms.
Latest Trends
• Combination checkpoint inhibitor + chemotherapy regimens.
• Liquid biopsy research for MPM-specific biomarkers.
• Use of AI in imaging analysis for faster detection.
• Development of next-gen TTF devices for better patient compliance.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=70867
Competitor Analysis
Major Players
• Bristol Myers Squibb (Opdivo® + Yervoy® combination therapy)
• Merck & Co., Inc. (Keytruda®)
• Novocure Ltd. (TTF devices)
• Roche Holding AG
• Eli Lilly & Company
• AstraZeneca plc
• Pfizer Inc.
• Boehringer Ingelheim
• Takeda Pharmaceutical Company Limited
• BeiGene Ltd.
• Amgen Inc.
• CStone Pharmaceuticals
• Zai Lab Ltd.
• Innovent Biologics
Competitive Summary
The MPM market is rapidly evolving, with immunotherapy developers and device manufacturers competing to improve survival outcomes through innovative combination regimens and supportive technologies.
Conclusion
The malignant pleural mesothelioma market is poised for growth as immunotherapy adoption, biomarker development, and multimodal treatment approaches reshape patient care. By 2034, earlier detection and wider access to advanced therapies will be key to improving survival rates.
Opportunities include:
• Developing cost-effective immunotherapy solutions for emerging markets.
• Expanding clinical trials in underrepresented regions.
• Integrating AI-powered diagnostics for faster and more accurate detection.
This report is also available in the following languages : Japanese (悪性胸膜中皮腫市場), Korean (악성 흉막 중피종 시장), Chinese (恶性胸膜间皮瘤市场), French (Marché du mésothéliome pleural malin), German (Markt für malignes Pleuramesotheliom), and Italian (Mercato del mesotelioma pleurico maligno), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/70867/malignant-pleural-mesothelioma-market#request-a-sample
Our More Reports:
Substance Use Disorder Market
https://exactitudeconsultancy.com/reports/70806/substance-use-disorder-market
Platinum-based Chemotherapy and Nephrotoxicity Market
https://exactitudeconsultancy.com/reports/70808/platinum-based-chemotherapy-and-nephrotoxicity-market
Metastatic Prostate Cancer Market
https://exactitudeconsultancy.com/reports/70810/metastatic-prostate-cancer-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Malignant Pleural Mesothelioma Market is expected to reach USD 2.11 billion by 2034 here
News-ID: 4144012 • Views: …
More Releases from Exactitude Consultancy
Low-Grade Glioma Market is expected to reach USD 2.75 billion by 2034
Low-grade gliomas (LGGs) are slow-growing primary brain tumors classified as WHO grade I or II, most commonly including astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. Although generally associated with better prognosis compared to high-grade gliomas, LGGs can progress to higher grades over time, necessitating long-term management.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70865
The LGG market is set for significant growth over the next decade, driven by advances in molecular profiling,…
Intrahepatic Cholangiocarcinoma Market is expected to reach USD 1.34 billion by …
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive form of bile duct cancer originating within the liver. It accounts for approximately 10-15% of primary liver cancers but has one of the poorest prognoses due to late-stage diagnosis and limited treatment options. Over recent years, genomic profiling has identified actionable mutations-including FGFR2 fusions, IDH1 mutations, and BRAF mutations-leading to the approval of targeted therapies and expanding treatment possibilities.
The iCCA market is…
High-Grade Glioma Market is expected to reach USD 9.92 billion by 2034
High-grade gliomas (HGGs) are aggressive brain tumors classified as WHO grade III (anaplastic astrocytoma, anaplastic oligodendroglioma) and grade IV (glioblastoma multiforme). They represent some of the most challenging cancers to treat due to their rapid growth, infiltrative nature, and high recurrence rates. Standard-of-care typically involves surgery, radiation, and chemotherapy, but median survival remains limited, especially for glioblastoma patients.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/70861
The next decade will…
Hairy Cell Leukemia Market is expected to reach $1.18 billion by 2034
Hairy cell leukemia (HCL) is a rare, slow-growing type of chronic B-cell leukemia characterized by the abnormal growth of B lymphocytes. The disease is named for the hair-like projections seen on the surface of cancer cells under a microscope. Despite being rare, HCL is one of the most treatable leukemias, with long remission periods achievable through targeted chemotherapy and immunotherapy.
Over the next decade, the HCL market will benefit from innovations…
More Releases for MPM
Reach Your Selected Location without Complications Caused Way with MPM Train Amb …
Thursday, July 03, 2025: It often happens that patients are referred to bigger cities to get better treatment that isn't available in the nearby locations, and only the best medical transport companies are effective enough to conduct the process of relocation successfully for patients. MPM Train Ambulance helps shift critical patients without making their health unstable or causing hindrance to their convenience and provides Train Ambulance in Patna that operate…
Mayzo's Polypropylene Thermoforming Customers Use MPM 2000 "Beta Nucleating Tech …
If you mold or sell polypropylene (PP) containers such as yogurts, wipes, and food packaging and want to meet your sustainability goals, Mayzo's Beta Nucleating Technology is a great option to add to your formulations.
Mayzo's customers that have incorporated its MPM 2000 "Beta Nucleating Technology" into their thermoforming production lines realize these four key benefits:
1-Achieve a down-weighting rate of at least 15% without sacrificing the physical properties and rigidity of…
Marketing Performance Management (MPM) Software Market Outlook 2022: Big Things …
The Latest Released Marketing Performance Management (MPM) Software market study has evaluated the future growth potential of Global Marketing Performance Management (MPM) Software market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics,…
Antimicrobial Gel Market Overview and Forecast Report 2019| Medline, MPM Medical …
The report comes out as an intelligent and thorough assessment tool as well as a great resource that will help you to secure a position of strength in the global Antimicrobial Gel market. It includes Porter’s Five Forces and PESTLE analysis to equip your business with critical information and comparative data about the Global Antimicrobial Gel Market. We have provided deep analysis of the vendor landscape to give you a…
Global Skin Ulcers Negative Pressure Therapy Market 2019 - Mimedx Group, Mpm Med …
Wound Care Markets Volume I: Skin Ulcers, strong growth in newer technologies has been the main driver of increased revenues, even as other, more traditional markets have begun to slow.
In 2019, the market size of Skin Ulcers Negative Pressure Therapy is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at…
Inkjet Papers and Films Global Market 2019: Key Players – Epson, HP, OJI, Fuji …
Inkjet Papers and Films Industry
Description
Wiseguyreports.Com Adds “Inkjet Papers and Films -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database
This report describes the development of the industry by upstream & downstream, industry overall and development, key companies, as well as type segment & market application and so on, and makes a scientific prediction for the development industry prospects on the basis of analysis,…
